UK Medtech One Year Post-Brexit Vote: Still In The Land Of Uncertainty
The UK's Brexit and a failed Conservative Party election strategy last month weigh heavily on the minds of local medtech businesses, looking ahead nervously at the type of trade deal the UK might finally strike with the EU. They could be waiting awhile, because the When and What are still not yet apparent – never mind that the Why still rankles with many UK medtechs. That much is clear from a brand new survey of companies, which also reveals the primacy of NHS access.
You may also be interested in...
2017 was a watershed year in many respects, politically, economically and commercially for many players in the medtech field. Where will the opportunities lie in 2018, will breakthrough medtech innovation still have a place among providers often riding on fumes when it comes to budgets, and is it all as bad as some would make out?
The pace of Brexit-related work that impacts the UK medtech industry shows no sign of slowing over the summer. In view of unexpected – uncomfortable for some – recent opinion poll findings, there is unlikely to be a significant change in somewhat febrile UK atmosphere anytime soon. And the future UK medtech regulatory situation still needs close attention.
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.